Nyxoah’s U.S. Launch Is Firing on All Cylinders—Why the Market May Be Underestimating the Scaling Setup

The immediate catalyst is clear. On March 23, Baird analyst David Rescott lowered his price target on Nyxoah to $4.62 from $5.87, maintaining a Neutral rating. His reasoning frames the core investment question: the U.S. rollout is "in its early days." This downgrade, coming just days after a similar cut from Stifel, reflects a cautious, wait-and-see stance on a critical growth driver.

The market's own reaction to this news is telling. The stock trades near the bottom of its 52-week range and below its 200-day moving average. This persistent skepticism suggests the market has already priced in significant execution risk for the U.S. launch. Baird's cut, therefore, may not be a new shock but a formal acknowledgment of a setup that traders have been grappling with for months.

The launch reality itself is mixed. Nyxoah secured FDA approval in August 2025 and began its commercial push in September. The initial results show promise but are still small-scale. The company reported $4.5 million in U.S. revenue for Q4, with a team of 25 sales reps targeting 125 of the 400 top hypoglossal nerve stimulation accounts. The expansion plan calls for 40 reps and 200 accounts in 2026, indicating a deliberate, phased approach.

The thesis here is tactical. Baird's downgrade signals cautious optimism, but the depressed price suggests the market has already discounted a high probability of early stumbles. If the early traction holds and the company can execute its expansion plan, the current valuation may represent a mispricing. The stock's position near its 52-week low creates a potential entry point for investors willing to bet on the successful scaling of the U.S. commercial operation.

Assessing the U.S. Launch Mechanics and Early Metrics

The mechanics of the U.S. launch are now in motion, with three near-term drivers coming into focus: sales force scaling, reimbursement clarity, and surgeon engagement. The company's plan is explicit and phased. It began with a team of 25 sales representatives focused on 125 of the 400 top hypoglossal nerve stimulation accounts. The expansion plan calls for scaling to 40 sales reps and 200 accounts in 2026. This deliberate ramp-up suggests management is prioritizing quality coverage and training over rapid, uncontrolled growth, which could help avoid early execution missteps.

Reimbursement, a critical barrier to hospital adoption, has been secured. The company reports that Medicare represented 10% and commercial payers 90% of U.S. Genio business. More importantly, there is clarity on the facility fee. The CMS interim C-code fee for the implant procedure is set at $31,526 per implant, which aligns with the permanent CPT code 64582. This uniform pricing removes a major source of uncertainty for new hospital accounts and streamlines the adoption process.

Surgeon engagement is the final piece of the early traction puzzle. The company has trained 145 surgeons across 125 high-volume HGNS accounts. Of the value analysis committee submissions made, 57 approvals were reported with no rejections by year-end. This 57% approval rate provides a concrete benchmark for the commercialization process. It shows that the product is gaining acceptance, but also that a significant portion of submissions are still pending, indicating a pipeline of potential future placements that will need to be converted.

The bottom line is that the launch is moving from concept to execution. The sales force expansion is on track, reimbursement is locked in, and surgeon engagement is building. The early metrics-$4.5 million in U.S. revenue for Q4 and a 57% VAC approval rate-are small but consistent with a commercial operation in its initial phase. For the stock, this steady progress is the counter-narrative to Baird's caution. It demonstrates that the fundamental mechanics of the catalyst are working, which could eventually justify a re-rating if the company hits its 2026 expansion targets.

Financial Impact and Valuation Setup

The financial picture is one of explosive top-line growth against a backdrop of persistent losses. In the latest quarter, revenue surged 331% year-over-year to €5.6 million. This dramatic jump is the direct result of the commercial launch, with the U.S. contribution now visible. Yet the company remains unprofitable, reporting a GAAP EPS of -€0.57. The bottom line is clear: the market is paying for future growth, not current earnings. The stock's valuation is entirely forward-looking.

This sets up a classic high-risk, high-reward scenario. The market capitalization of $199.5 million implies that investors are betting on the successful scaling of the U.S. launch to drive the kind of growth analysts forecast. Consensus calls for 38.6% annual revenue growth and a 17.4% EPS growth rate. The current price, however, discounts the early, small-scale revenue. The stock's recent 0.64% drop to $6.24 suggests the market views the initial $4.5 million in U.S. revenue as insufficient to justify the premium already baked into the shares. It's a classic "show me" moment.

The risk/reward hinges on execution. The valuation assumes the company can hit its 2026 expansion targets-scaling the sales force and converting its surgeon pipeline. Any stumble in this plan would validate the market's skepticism and likely pressure the stock further. On the flip side, if the company demonstrates it can accelerate adoption and hit its growth forecasts, the current low valuation could represent a significant mispricing. The tactical setup is defined by this binary outcome: the stock is priced for either a successful scaling or a disappointing execution.

Catalysts and Risks: What to Watch Next

The tactical setup now hinges on a few key near-term data points. The first is the company's own guidance. Nyxoah is scheduled to report its Q1 2026 results on March 19, 2026. The market will scrutinize its U.S. revenue guidance for the quarter, looking for confirmation that the initial $4.5 million in Q4 is the start of a meaningful ramp. Any miss against the consensus forecast of 38.6% annual revenue growth would validate the current skepticism and likely pressure the stock further.

The pace of sales force expansion is the second critical metric. Management's plan calls for scaling from 25 reps to 40 reps and from 125 to 200 accounts in 2026. Investors need to see this plan executed. A delay or slowdown in hiring would signal operational friction, while hitting or exceeding these targets would demonstrate the commercial engine is building as intended.

A leading indicator of commercial adoption is the value analysis committee (VAC) approval rate. The company reported a 57% approval rate with no rejections by year-end. Monitoring the trend in VAC submissions and approvals in the coming quarters is essential. A rising approval rate would signal growing hospital acceptance, while stagnation or a decline would be a red flag for the scaling thesis.

The primary risk is straightforward: U.S. revenue growth remains slower than the 38.6% annual forecast. The stock's depressed valuation implies the market has already discounted a high probability of early stumbles. If the company fails to accelerate its revenue trajectory, the valuation gap between the current price and the growth narrative will persist, and the stock could drift lower. The catalyst for a re-rating is clear-consistent execution on the expansion plan and a visible acceleration in U.S. sales. Until then, the setup remains a binary bet on successful scaling.